Shares of NovoCure (NVCR) have gained 8% over the past four weeks to close the last trading session at 17.10,buttherecouldstillbeasolidupsideleftinthestockifshort−termpricetargetsofWallStreetanalystsareanyindication.Goingbythepricetargets,themeanestimateof35.14 indicates a potential upside of 105.5%.The mean estimate comprises seven short-term price targets with a standard deviation of 6.74.Whilethelowestestimateof27 indicates a 57.9% increase from the current pric ...